Literature DB >> 230894

Tamoxifen-induced tumor stimulation and withdrawal response.

S Legault-Poisson, J Jolivet, R Poisson, M Beretta-Piccoli, P R Band.   

Abstract

A postmenopausal breast cancer patient with a measurable lung metastasis was treated with tamoxifen. The tumor doubling time of the pulmonary lesion was 140 days during spontaneous growth and 52 days during tamoxifen therapy, an almost threefold increase in tumor growth rate. This stimulation persisted fro 1 month after discontinuation of tamoxifen and was followed thereafter by a withdrawal regression lasting greater than 6 months. Awareness of the possible tumor growth enhancement with tamoxifen is of importance especially in view of its prolonged activity. Hormone withdrawal regression may occur following tamoxifen therapy, and a sufficient time interval should therefore elapse between cessation of tamoxifen and initiation of other therapeutic modalities.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 230894

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  15 in total

1.  Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer.

Authors:  Xiaonan Hou; Fei Huang; Luciana F Macedo; Sean C Harrington; Karen A Reeves; Ann Greer; Friedrich Graf Finckenstein; Angela Brodie; Marco M Gottardis; Joan M Carboni; Paul Haluska
Journal:  Cancer Res       Date:  2011-10-31       Impact factor: 12.701

2.  Tamoxifen flare hypercalcemia: an additional support for gallium nitrate usage.

Authors:  Govinda Pillai Arumugam; Sengoden Sundravel; Palanivel Shanthi; Panchanadham Sachdanandam
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

3.  Structural insights into selective agonist actions of tamoxifen on human estrogen receptor alpha.

Authors:  Sandipan Chakraborty; Pradip Kumar Biswas
Journal:  J Mol Model       Date:  2014-07-25       Impact factor: 1.810

Review 4.  Hormone resistance, invasiveness, and metastatic potential in breast cancer.

Authors:  R Clarke; E W Thompson; F Leonessa; J Lippman; M McGarvey; T L Frandsen; N Brünner
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

5.  Can the clinical course of cancer be influenced by non-antineoplastic drugs?

Authors:  L J Brandes; L A Friesen
Journal:  CMAJ       Date:  1995-09-01       Impact factor: 8.262

Review 6.  Mechanisms of hormone resistance in breast cancer.

Authors:  K B Horwitz
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

7.  Tamoxifen-stimulated growth of breast cancer due to p21 loss.

Authors:  Abde M Abukhdeir; Michele I Vitolo; Pedram Argani; Angelo M De Marzo; Bedri Karakas; Hiroyuki Konishi; John P Gustin; Josh Lauring; Joseph P Garay; Courtney Pendleton; Yuko Konishi; Brian G Blair; Keith Brenner; Elizabeth Garrett-Mayer; Hetty Carraway; Kurtis E Bachman; Ben Ho Park
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-27       Impact factor: 11.205

Review 8.  William L. McGuire Memorial Symposium. Drug resistance to tamoxifen during breast cancer therapy.

Authors:  D M Wolf; V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

9.  Medical adrenalectomy in patients with advanced breast cancer resistant to anti-oestrogen treatment.

Authors:  R M Murray; P Pitt
Journal:  Breast Cancer Res Treat       Date:  1981       Impact factor: 4.872

10.  Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice.

Authors:  D M Wolf; V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.